Virginia biotech Neoantigenics announces early stage collaboration with Pfizer.
Neoantigenics, a biotech spin-out from the University of Virginia (UVa), has announced an early stage research and development (R&D) collaboration with pharmaceutical firm Pfizer.
The two will be working on the development of antibody-based therapeutics targeting human egg-cell biomarkers which could impact on a wide array of cancers.
In addition, Pfizer joined in a venture round in Neoantigenics through its early-stage life sciences focused Pfizer Seed Fund. Other participants in the round, which was for an unspecified amount, include innovation acceleration organisation the Centre for Innovative Technology, which made its investment through its GAP Fund, and the Commonwealth Research Commercialisation Fund.
Brian Pollok, CEO at Neoantigenics, said: “Our collaboration with Pfizer supports the unique foundational science behind Neoantigenics, and demonstrates an innovative way for start-ups like us to effectively work with a leading pharmaceutical company.”